Eprosartan: A Review of its Use in the Management of Hypertension

Authors: Robins, Gayle W.; Scott, Lesley J.

Source: Drugs, Volume 65, Number 16, 2005 , pp. 2355-2377(23)

Buy & download fulltext article:

Price: $68.55 plus tax (Refund Policy)

Abstract:

The angiotensin II receptor antagonist eprosartan is approved for the treatment of essential hypertension and may be administered using a convenient once-daily regimen. The drug is a well tolerated and effective antihypertensive agent with benefit in the secondary prevention of cerebrovascular events, independent of blood pressure (BP)-lowering effects. Eprosartan has a low potential for serious adverse events and has not been associated with clinically significant drug interactions, establishing it as a promising agent for combination antihypertensive strategies. Unlike ACE inhibitors such as enalapril, eprosartan does not have a tendency to cause persistent nonproductive cough. Accordingly, eprosartan represents a useful therapeutic option in the management of patients with hypertension, including those who have had a stroke and those with co-morbid type 2 diabetes mellitus.

Keywords: Adis Drug Evaluations; Eprosartan; Hypertension

Document Type: Research article

Affiliations: 1: Adis International Limited, Auckland, New Zealand

Publication date: 2005-01-01